Interventional, Single-site, Open-label, Reduced/Staged, Multiple-dose Study Investigating the Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Patients With Renal Impairment and in Healthy Subjects

Trial Profile

Interventional, Single-site, Open-label, Reduced/Staged, Multiple-dose Study Investigating the Pharmacokinetic Properties of Idalopirdine (Lu AE58054) in Patients With Renal Impairment and in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Nov 2015

At a glance

  • Drugs Idalopirdine (Primary)
  • Indications Alzheimer's disease; Cognition disorders
  • Focus Pharmacokinetics
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 06 Nov 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 29 Sep 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 21 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top